SEP 16, 2019 12:39 PM PDT

Injectable Hydrogel Found Safe for Heart Repair

WRITTEN BY: Nouran Amin

The first successful in-human clinical trial of an injectable hydrogel that aims to repair heart damage and restore cardiac function was recently conducted by Ventirx—a University of San Diego spin-off company. The clinical trial was an FDA-approved Phase 1 study targeted for heart failure patients who recently suffered cardiac arrest. The study was the first to test an injectable hydrogel made to improve cardiac tissue. The hydrogel was made form a natural scaffolding of cardiac muscle tissue known as the heart tissues extracellular matrix, or ECM. This is especially crucial because studies shave shown that ECM hydrogels are highly effective for other conditions such as poor blood circulation from peripheral artery disease.

Findings of the injectable hydrogel, known as VentriGel, has been reported in the latest issue of American College of Cardiology. Following heart attack, the study examined 15 patients who sustained moderate damage in the left ventricle chamber of the heart. Each one of those patients received up to 18 injections of VentriGel into the damaged areas.

"Although the study was designed to evaluate safety and feasibility and not designed to show whether VentriGel effectively helps improve heart function, we observed some improvements in patients," said Karen Christman, the paper's senior author and a professor of bioengineering in the Jacobs School of Engineering and the Institute of Engineering in Medicine at UC San Diego. "For example, patients could walk longer distances. We also observed signs of improving heart function in patients who experienced a heart attack more than one year prior to treatment."

Karen Christman, professor in the Department of Bioengineering at UC San Diego, led the development of Ventrigel, a hydrogel to repair heart tissue after heart attacks.

(CREDIT: University of California-San Diego)

In patients who suffered a heart attack within the past 2 to 36 months, VentriGel can be injected in a safe manner through a catheter. Once in, the damaged cardiac muscle can be repaired from the scaffold presented by the VentriGel. This allows healthy cells to migrate, more cardiac muscle formation, less scar tissue, and improvements in cardiac function.

VentriGel is made from the cardiac connective tissue of pigs, which is cleansed of heart muscle cells through a detailed process and then freeze-dried and milled into powder form. After, the powder becomes liquid and is then is ready to be injected in the heart muscle. The minimally invasive procedure will take the liquid and convert it to a gel once it reaches body temperature.

Watch this video below to learn more:

Positive results of the study are now allowing researchers to prepare for the Phase 2 clinical trial which will allow them to determine how VentriGel can improve the quality of life for heart failure patients.

Source: University of California-San Diego

About the Author
  • Nouran enjoys writing on various topics including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
OCT 17, 2019
Health & Medicine
OCT 17, 2019
High Risk: Seizures and Coma Linked to Use of Synthetic Cannabinoids in Adolescents
A recent study by the American Academy of Pediatrics states that exposure to acute synthetic cannabinoid toxicity is far more dangerous to the adolesc...
OCT 17, 2019
Technology
OCT 17, 2019
How Bitcoins Can Advance Medication Usage
Will futuristic concepts from the world of technology likely find a place in our medicine cabinet? Maybe! The new concept has been known as ‘cryptoph...
OCT 17, 2019
Drug Discovery & Development
OCT 17, 2019
Diabetic Drugs Offer Protection Against Kidney Failure
Kidney failure is a consequence of diabetic kidney disease--roughly 3 million people are seeking treatment worldwide for kidney failure and the numbers are...
OCT 17, 2019
Genetics & Genomics
OCT 17, 2019
DNA Construction Kit Could Drive Down Costs of Immune Therapy
Researchers at KU Leuven in Belgium have created a DNA construction kit that, when injected into muscle cells, enables sheep to produce new antibodies to f...
OCT 17, 2019
Drug Discovery & Development
OCT 17, 2019
AI Exponentially Accelerates Drug Development
Research and development for new drugs is both an expensive and lengthy process, often lasting years, if not decades. With the development of artificial in...
OCT 17, 2019
Drug Discovery & Development
OCT 17, 2019
New Potential Early Stage Treatment for Parkinson's
Parkinson’s Disease is the second most common neurodegenerative condition, affecting 35 million people globally. Currently without a cure, researcher...
Loading Comments...